Cyclic Peptides for Colon Cleansing via GC-C Receptor Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current colon preparation methods for colonoscopies are often inadequate, leading to lower adenoma detection rates, longer procedural times, and shorter intervals between examinations, necessitating the development of safe, effective, and well-tolerated colon preparations for a broader patient population to reduce the risk of colon cancer.
Innovation Solution
The use of specific peptides or their pharmaceutically acceptable salts, which comprise particular amino acid sequences, including covalent bonds, to activate the Guanylate Cyclase C (GC-C) receptor, promoting effective colon cleansing and treating various gastrointestinal disorders, including colon cancer, by enhancing fluid secretion and intestinal transit.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional colon preparation methods are used, then bowel cleansing is achieved, but patient tolerance and effectiveness are insufficient leading to inadequate preparation
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of the active compound from linear to cyclic form (e.g., linaclotide to ciclesonide), which fundamentally alters the molecule's properties including stability, receptor binding affinity, and metabolic resistance. This structural transformation resolves the contradiction by maintaining bowel preparation effectiveness while reducing degradation and improving patient tolerance.
Solution Approach 2:
The patent employs composite material principles by creating cyclic peptides that combine multiple amino acid residues into a unified ring structure with specific disulfide bridges. This composite structure integrates stability, receptor specificity, and metabolic resistance into a single molecular entity, achieving both effective bowel preparation and reduced side effects.
2Manufacturing precision
If stronger colon preparation is used to improve cleansing effectiveness, then bowel preparation quality increases, but patient tolerance decreases
Solution Approach 1:
The patent applies local quality by designing the cyclic peptide structure with specific functional regions: disulfide bridge regions for stability, GC-C receptor binding regions for effectiveness, and metabolically resistant regions for reduced side effects. Each region of the molecule performs a specific function, allowing the compound to achieve high preparation quality while minimizing harmful effects through localized structural optimization.
3Reliability
If existing peptide structures are used, then GC-C receptor activation is achieved, but metabolic degradation reduces effectiveness
Solution Approach 1:
The patent applies beforehand cushioning by pre-forming the cyclic structure with disulfide bridges that protect the peptide backbone from enzymatic degradation before the compound reaches its site of action. This structural protection acts as a cushion against metabolic breakdown, ensuring the compound remains intact and active throughout the gastrointestinal tract, thereby extending duration of action while maintaining receptor activation effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides effectively prepare subjects for colonoscopy and treat gastrointestinal disorders by improving bowel preparation, reducing pain, and increasing stool frequency and consistency, thereby enhancing the efficacy of colonoscopies and managing gastrointestinal conditions.
Implementation Method 1
enhancing fluid secretion and intestinal transit
Data Source
AI summary
The present invention provides peptides and compositions that are useful for the treatment of gastrointestinal disorders or for colon cleansing. The present invention also provides compositions and methods of treating gastrointestinal disorders and pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms.